HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open
Mar 04, 2025 12:26 HKT |  |
|
Hua Medicine Awarded Shanghai Innovative Enterprise Headquarters
Mar 03, 2025 14:50 HKT |  |
|
CGFNS International to Change Its Name to TruMerit
Feb 26, 2025 07:00 HKT |  |
|
Goldman Sachs Raises Everest Medicines' Target Price to HK$48.32 on Stronger Commercial and R&D Outlook
Feb 19, 2025 14:42 HKT | |
|
CGFNS International Reports Nurse Migration Rates to the U.S. Remained High in 2024
Feb 12, 2025 08:00 HKT | |
|
An Incredible KLAS Triple-Award Win for AGFA HealthCare!
Feb 10, 2025 22:00 HKT |  |
|
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
Feb 04, 2025 18:00 HKT |  |
|
Where is the next Chinese drug that will make MNCs compete to grab orders?
Jan 09, 2025 21:34 HKT | |
|
Biotech Startups Get a Boost: ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
Jan 08, 2025 22:30 HKT |  |
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy
Jan 02, 2025 10:52 HKT |  |
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area
Dec 18, 2024 14:29 HKT | |
|
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY
Dec 17, 2024 10:58 HKT | |
|
CIL Announces Breakthrough in Benzene Recovery, Addressing Cost, Environmental, and Supply Challenges for OLED Display Manufacturers
Dec 12, 2024 22:00 HKT |  |
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau
Dec 12, 2024 12:11 HKT | |
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership
Dec 11, 2024 11:06 HKT | |
|
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Dec 10, 2024 20:30 HKT |  |
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Dec 04, 2024 11:08 HKT | |
|
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong
Dec 02, 2024 10:34 HKT | |
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate
Nov 30, 2024 21:08 HKT | |
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC
Nov 30, 2024 20:34 HKT | |
|